CDKN2B gene rs1063192 polymorphism decreases the risk of glaucoma

Zhenxian Hu; Chenliang He

doi:10.18632/oncotarget.15504

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CDKN2B gene rs1063192 polymorphism decreases the risk of glaucoma

Zhenxian Hu and Chenliang He _

PDF | HTML | How to cite

Oncotarget. 2017; 8:21167-21176. https://doi.org/10.18632/oncotarget.15504

Metrics: PDF 1430 views | HTML 1833 views | ?

Abstract

Zhenxian Hu1, Chenliang He1

1Department of Ophthalmology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, China

Correspondence to:

Chenliang He, email: [email protected]

Keywords: CDKN2B, single nucleotide polymorphism, glaucoma, meta-analysis, rs1063192

Received: December 20, 2016 Accepted: February 08, 2017 Published: February 18, 2017

ABSTRACT

The aim of this meta-analysis was to evaluate the association between cyclin-dependent kinase Inhibitor-2B (CDKN2B) gene rs1063192 polymorphism and glaucoma risk. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. A total of 14 case-control studies involving 11,316 cases and 24,055 controls were included. Meta-analysis showed that CDKN2B gene rs1063192 polymorphism was associated with a decreased risk of glaucoma. Stratification analysis of ethnicity indicated that rs1063192 polymorphism decreased the risk of glaucoma among Caucasians and Asians. Stratification analysis by type of glaucoma revealed that rs1063192 polymorphism conferred a protective factor of primary open-angle glaucoma (POAG) and non-POAG. Stratification by source of controls uncovered an association between rs1063192 polymorphism and glaucoma in groups of population-based controls. In conclusion, this meta-analysis indicates that CDKN2B gene rs1063192 polymorphism is significantly associated with a decreased risk of glaucoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15504

Publication Alerts

Research Papers:

CDKN2B gene rs1063192 polymorphism decreases the risk of glaucoma

Abstract